EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Oncology Pharma's Enterprise Value is $0.00 Mil.
Oncology Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2004 was $-0.77 Mil. Therefore, Oncology Pharma's EV-to-FCF for today is -0.01.
The historical rank and industry rank for Oncology Pharma's EV-to-FCF or its related term are showing as below:
ONPH'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.85 Med: 0 Max: 0.49
Current: -0.5
During the past 7 years, the highest EV-to-FCF of Oncology Pharma was 0.49. The lowest was -0.85. And the median was 0.00.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oncology Pharma's PE Ratio (TTM) for today is calculated as:
Oncology Pharma's share price for today is $0.07.
Oncology Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2004 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Oncology Pharma EV-to-FCF Related Terms
Oncology Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Oncology Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Shell Companies subindustry, Oncology Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncology Pharma EV-to-FCF vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Oncology Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Oncology Pharma's EV-to-FCF falls into.
Oncology Pharma's current Enterprise Value is $0.00 Mil.
Oncology Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2004 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncology Pharma (ONPH) has a EV-to-FCF of -0.01 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Oncology Pharma and its competitors.
Is Oncology Pharma's EV-to-FCF too high?
Oncology Pharma's current EV-to-FCF is -0.01.
How does Oncology Pharma's EV-to-FCF compare to TAUG and IMUN?
Oncology Pharma's EV-to-FCF of -0.01 can be compared against companies in the Diversified Financial Services industry. The industry median EV-to-FCF is 3.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Diversified Financial Services company?
The median EV-to-FCF among Diversified Financial Services companies is 3.41, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Oncology Pharma and its competitors. For the Diversified Financial Services industry, the median EV-to-FCF is 3.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncology Pharma's current EV-to-FCF is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncology Pharma stock overvalued right now?
Oncology Pharma (ONPH) has a current EV-to-FCF of -0.01. The current EV-to-FCF is -0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Oncology Pharma (ONPH), the current EV-to-FCF is -0.01 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONPH has been successfully added to your 